COVID-19 testing currently available by appointment. Monoclonal Antibody Infusion REGEN-COV currently available by appointment.


Symptoms of COVID-19 usually start 4-5 days after a person is infected with the virus but it can take up to 14 days for symptoms to occur in some people:

How is COVID-19 spread?

The virus is primarily spread from person to person. This usually happened when an infected person coughs, sneezes, or talks near other people.


Testing is performed by obtaining a thorough swab of the nose.

Nucleic acid tests (PCR) look for the genetic material of the virus. This is considered the most accurate test but often takes several days to result.


Antigen Test looks for proteins from the virus and results are usually available in 15 minutes.

Treatment Options

Most cases can be treated with rest and common over the counter remedies. Treatment with Vitamin C, Zinc, Vitamin D, and B12 can help the bodies immune system to fight off infection.


Tylenol should be used to control fever and body aches. Expectorants can be used to help control cough and congestion.


In some cases your doctor may prescribe anti-inflammatories to help with your symptoms.


Antibiotics may be used to treat secondary infection.


In severe cases a person may require breathing treatments, oxygen, or mechanical ventilation.

REGEN-COV - Monoclonal Antibody Infusion

Casirivimab and Imdevimab COVID-19 Emergency Use Authorization November 2020

FDA issued an emergency use authorization for the investigational monoclonal antibodies casirivimab and imdevimab for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are ≥12 years of age weighing ≥40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Casirivimab and imdevimab must be administered together and are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy (or an increase in baseline oxygen flow rate in those on chronic oxygen therapy because of an underlying non-COVID-19 related comorbidity) due to COVID-19. While the safety and efficacy of these investigational agents continues to be evaluated, casirivimab and imdevimab were shown in a clinical trial to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo. A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19.